Multicellular life requires two complementary programs: must know when to divide (and do so correctly), and they must know when to die (and do so cleanly). The cycle governs the former; apoptosis governs the latter. Both are tightly regulated, both fail in cancer, and both are major targets of therapeutic intervention.
The Cell Cycle: Four Phases
The cycle is the sequence of events a undergoes to duplicate its contents and divide into two daughter . It has four phases:
G1 Phase (Growth 1)
The grows in size, synthesizes and organelles, and responds to growth signals. This is the primary decision point: does the commit to division or exit the cycle?
The G1/S checkpoint (also called the restriction point) is the main control gate. Before passing it, the checks:
- Sufficient nutrients and growth factor signaling
- integrity (no unrepaired damage)
- Adequate size
Once past the restriction point, division is committed even if growth factors are withdrawn.
S Phase (DNA Synthesis)
The entire is replicated. Each of the ~3 billion pairs in a human is copied. Origin firing, replication fork progression, and Okazaki fragment ligation all occur here. Duration: ~8 hours in human .
G2 Phase (Growth 2)
The grows further and prepares for mitosis. The G2/M checkpoint verifies that replication is complete and error-free before division proceeds.
M Phase (Mitosis)
The physically divides. condense, the mitotic spindle assembles, are segregated to opposite poles, and the cleaves (cytokinesis). Duration: ~1 hour. Comprises: prophase, prometaphase, metaphase, anaphase, telophase, cytokinesis.
The spindle assembly checkpoint (SAC) within M phase verifies that every is properly attached to the spindle before are pulled apart. A single unattached kinetochore can halt the entire — preventing chromosomal segregation errors.
CDKs and Cyclins: The Molecular Clock
cycle transitions are driven by cyclin-dependent kinases (CDKs) — kinases that are only active when bound to their regulatory subunit, cyclins. Cyclin levels oscillate through the cycle; CDK levels are relatively constant.
| CDK-Cyclin complex | Phase | Key substrates |
|---|---|---|
| CDK4/6 – Cyclin D | G1 | RB (retinoblastoma protein) |
| CDK2 – Cyclin E | Late G1 → S | RB, histone H1, replication factors |
| CDK2 – Cyclin A | S phase | Replication proteins, SRC |
| CDK1 – Cyclin A/B | G2 → M | Nuclear lamins, condensins, kinetochore proteins |
The oscillating CDK activity creates a cycle clock — once high CDK activity is established, it tends to be self-reinforcing (positive feedback), ensuring sharp transitions rather than gradual drifts.
The RB/E2F Axis: The Restriction Point Switch
The retinoblastoma (RB) is a central cycle brake. In quiescent , RB is hypophosphorylated and binds E2F , preventing them from activating S-phase .
When receive growth signals → CDK4/6-Cyclin D is activated → RB is phosphorylated → RB releases E2F → E2F activates required for S phase entry (Cyclin E, CDK2, synthesis , etc.).
This creates a bistable switch: once CDK4/6 activity rises enough to start phosphorylating RB, released E2F activates Cyclin E/CDK2, which further phosphorylates RB, releasing more E2F — positive feedback that drives the past the restriction point irreversibly.
RB is mutated or functionally inactivated in virtually all cancers — either by direct (retinoblastoma, lung cancer, etc.), CDK4/6 amplification, or loss of CDKN2A (which encodes the CDK4/6 inhibitor p16/INK4a).
The RB/CDK4/6 axis is now a major drug target. Three CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) are approved for hormone -positive, HER2-negative breast cancer. They work by blocking CDK4/6 → preventing RB phosphorylation → maintaining E2F repression → blocking S-phase entry. They are now standard of care in ER+/HER2- metastatic breast cancer, demonstrating that tumor suppressor understanding directly translates to therapy.
Checkpoints: Quality Control Gates
Checkpoints are surveillance mechanisms that halt cycle progression when damage or errors are detected:
DNA Damage Checkpoints
If is damaged (double-strand breaks, single-strand gaps, replication fork stalling):
- ATM/ATR kinases are activated
- ATM/ATR phosphorylate CHK1/CHK2 kinases
- CHK1/CHK2 phosphorylate CDC25 phosphatases → targeting them for degradation
- Without CDC25, CDK-Cyclin complexes remain inhibitory-phosphorylated → cycle arrest
The arrest provides time for repair. If repair is successful, the checkpoint is relieved and the cycle resumes. If damage is too severe, the enters apoptosis.
p53: The Guardian of the Genome
TP53 (encoding p53) is the most frequently mutated in human cancer (~50% of all tumors). p53 is a that responds to diverse cellular stresses:
- Activated by ATM/ATR in response to damage
- Activated by oncogene activation (through ARF)
- Activated by hypoxia, ribosomal stress, oxidative stress
Activated p53 drives expression of:
- CDKN1A (p21) → CDK inhibitor → G1/S and G2/M arrest
- GADD45 → G2/M arrest
- BAX, PUMA, NOXA → pro-apoptotic
- MDM2 → negative feedback (MDM2 ubiquitinates p53 for degradation)
When damage is mild, p53 drives arrest and repair. When damage is severe or persistent, p53 drives apoptosis — eliminating the to prevent propagation of damage.
Apoptosis: Programmed Cell Death
Apoptosis is a genetically encoded death program that eliminates without triggering inflammation. It's essential for:
- Development: sculpting fingers by killing inter-digit ; eliminating excess
- Immune regulation: deleting self-reactive T in the thymus
- Quality control: eliminating -damaged or virally infected
Apoptosis produces characteristic morphology: shrinkage, chromatin condensation, nuclear fragmentation, blebbing, and formation of apoptotic bodies that are phagocytosed by neighboring . Unlike necrosis (uncontrolled rupture), apoptosis is clean — no inflammatory spill.
The Intrinsic Pathway (Mitochondrial)
Activated by internal stress: damage, growth factor withdrawal, hypoxia, ER stress.
Stress signal
↓
Pro-apoptotic BCL-2 proteins activated (BAX, BAK, BIM, PUMA, NOXA)
↓ overwhelm anti-apoptotic BCL-2/BCL-XL
Mitochondrial outer membrane permeabilization (MOMP)
↓
Cytochrome c release
↓
APAF-1 + cytochrome c + dATP → Apoptosome
↓
Caspase-9 activation
↓
Executioner caspases (Caspase-3, Caspase-7)
↓
Cellular demolition: DNA fragmentation, protein cleavage, membrane changes
The Extrinsic Pathway (Death Receptor)
Activated by external death signals from immune :
Death ligand (FasL, TRAIL, TNF) binds Death receptor (Fas, DR4/5, TNFR1)
↓
DISC (Death-Inducing Signaling Complex) assembles
↓
Caspase-8 activation
↓
Direct caspase-3 activation (Type I cells)
OR
BID cleavage → tBID → engages intrinsic pathway (Type II cells)
BCL-2 Family: The Apoptosis Control System
The BCL-2 family governs the intrinsic . Members fall into three groups:
Anti-apoptotic: BCL-2, BCL-XL, BCL-W, MCL-1, A1 — promote survival by binding and inhibiting pro-apoptotic members
Multi-domain pro-apoptotic: BAX, BAK — form pores in the mitochondrial when activated
BH3-only : BIM, PUMA, NOXA, BAD, BID — sensors of stress signals; activate BAX/BAK or neutralize anti-apoptotic
The balance between pro- and anti-apoptotic BCL-2 family members determines whether a survives or undergoes apoptosis. Cancer often tip this balance by overexpressing anti-apoptotic members (BCL-2 overexpression in follicular lymphoma via t(14;18) translocation).
Venetoclax is a BH3 mimetic drug that inhibits BCL-2 — it displaces BIM and other BH3-only from BCL-2, activating apoptosis. Approved for CLL, AML, and multiple myeloma, venetoclax represents the clinical validation of the BCL-2 family as a drug target.
Cancer as Cell Cycle and Apoptosis Failure
Cancer is, at its core, a disease of uncontrolled cycle progression and apoptosis evasion. The Hallmarks of Cancer (Hanahan and Weinberg) include:
- Sustained proliferative signaling — oncogenic KRAS, EGFR ; growth factor self-sufficiency
- Evasion of growth suppressors — RB inactivation; loss of contact inhibition
- Resisting death — BCL-2 overexpression; p53 ; anti-apoptotic survival signals
- Enabling replicative immortality — telomerase reactivation; bypassing senescence
Nearly every cycle regulator we've discussed in this chapter is mutated, amplified, or functionally altered in some cancer type. The list of drugs targeting these has grown dramatically in the targeted therapy era.
Cell Cycle in Bioinformatics
cycle analysis appears frequently in computational biology:
cycle phase inference: Single- data contains a cycle signal — cycling express specific in S phase (MCM2, RRM2, PCNA) and G2/M (CCNB1, CDC20, BUB1). Tools like Seurat and scran include cycle scoring to identify cycling and regress out cycle effects when it's a confounder in analysis.
Proliferation signatures: Bulk scores based on cycle (like the Ki67 ) predict tumor growth rates and prognosis.
Checkpoint analysis: ChIP-seq for p53 binding sites reveals the -wide transcriptional response to damage. ATAC-seq shows how chromatin accessibility changes as enter/exit the cycle.
Understanding the cycle at the mechanistic level allows you to interpret these computational signals correctly — recognizing when changes reflect genuine biological responses versus cycle effects that need to be controlled for.